Bionano Genomics Inc logo

Bionano Genomics Inc(BNGO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.82
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BNGO

11/20/2026: BNGO (1-star) is currently NOT-A-BUY. Pass it for now.

Bionano Genomics Inc is a life sciences instrumentation company that provides optical genome mapping systems and bioinformatics software to detect complex structural genomic variants. Its primary business strengths include pioneering technology like the Saphyr and Stratys platforms and sticky consumable flow-cell streams. The core investment opportunity centers on the transition of optical genome mapping into routine clinical diagnostics backed by expanding reimbursement. However, key risks include persistent operating losses, tight cash reserves, and intense competition from larger sequencing firms. The stock suits risk-tolerant growth investors willing to monitor clinical adoption milestones and cash management execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in a high-growth genomics niche, revenue scaling has been uneven and offset by ongoing cash burn.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp episodic rallies driven by clinical milestones or adoption updates when technical momentum turns positive.
Value investorWeak fitThe company lacks current profitability and positive net income, making traditional value metrics inapplicable.
Dividend investorWeak fitBionano Genomics does not pay dividends as it reinvests all capital into business operations.
Low-risk investorWeak fitHigh share price volatility and micro-cap status expose investors to significant capital risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock exhibits high beta and sensitivity to market sentiment and micro-cap liquidity swings.
Valuation riskMedium / highValuation is heavily dependent on future revenue realization and long-term clinical adoption milestones.
Competition risk (next-generation sequencing and genomic analysis platforms)HighWell-capitalized sequencing giants continuously advance alternative technologies that compete for lab budgets.
Business qualityMediumProprietary technology offers unique scientific utility, but financial scale and profitability remain constrained.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighSuccess relies heavily on commercial execution, lab workflow integration, and securing broader reimbursement.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.50M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 246.3K shares
Beta 1.71
52 Weeks Range 0.81 - 2.23
Updated Date 11/20/2026
52 Weeks Range 0.81 - 2.23
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.96

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Medical Instruments & Supplies

BUY participation
50.0%
Active BUY / eligible
1 / 2
30-Day BUY Count Change
+1

Eligible universe: 2 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -54.76%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BNGO receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
BNGO has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+76.4%) is partially offset by weak cash generation (FCF margin -57.3%), negative revenue growth (-7.4%), weak profitability (net margin -92.6%).

Financial Health Rating

★★★★★
BNGO's financial health is soft, with the relatively strongest area being solid liquidity, including working-capital and asset support (WC/assets 30.5%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is BNGO's strongest growth driver at +76.4% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+76.3%, strong) is also strong, while revenue growth (-7.4%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 25.1% (moderate) and 91.6% of outstanding shares are publicly tradable (strong). Insider ownership of 2.32% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Renaissance Technologies Corp 1.14%
GSA Capital Partners LLP 1.11%
Carret & Company Inc 0.93%
Geode Capital Management, LLC 0.67%
Acadian Asset Management LLC 0.66%

Unit Economics (Per $1K Revenue)

★★★★★
BNGO generates approximately $220 of gross profit, $-1,169 of operating income, and $-573 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.25% (Tax Credit)

Quantitative Style Profile

★★★★★
BNGO has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Instrument SystemsSales and leases of Saphyr and Stratys optical genome mapping hardware instruments to research and clinical labs.Upfront hardware sales establish the installed base that drives future recurring consumable usage.
ConsumablesFlow cells, labeling kits, and reagent packs consumed during routine sample processing on Bionano hardware.Provides a sticky, recurring revenue stream as laboratory testing volume scales over time.
Services and SoftwareSoftware licenses for NxClinical bioinformatics platforms, support contracts, and genomic analysis services.Enhances product stickiness by providing essential data analysis and clinical reporting tools.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 12.03M
Price to Sales(TTM) 0.37
Enterprise Value 12.03M
Price to Sales(TTM) 0.37
Enterprise Value to Revenue 0.39
Enterprise Value to EBITDA -0.18
Shares Outstanding 13.99M
Shares Floating 12.81M
Shares Outstanding 13.99M
Shares Floating 12.81M
Percent Insiders 2.32
Percent Institutions 25.12

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.